Mechanism of Action

Bioregulators act primarily through three mechanisms.

1. Mechanism One

   Direct interaction with chromatin and gene-promoter regions.

   Short peptide bioregulators are small enough to translocate into the nucleus, where peer-reviewed research has demonstrated their capacity to bind specific DNA sequences and modulate gene expression directly. This is the foundational mechanism of the Khavinson-lineage peptides and the basis for their tissue-specific regulatory action.

2. Mechanism Two

   Modulation of peptide signaling networks within tissues.

   Beyond direct gene regulation, bioregulators participate in tissue-specific signaling cascades, modulating the expression and activity of downstream regulatory peptides. The result is a coordinated regulatory effect across multiple cell types within an organ system.

3. Mechanism Three

   Restoration of endogenous regulatory peptide pools.

   Endogenous regulatory peptide pools decline with age, disease, or chronic stress. Therapeutic administration of analogous or identical short peptides restores these pools to their native concentrations, allowing the body's regulatory architecture to resume its normal homeostatic operation.

The defining characteristic.

The mechanisms above are tissue-specific. A given bioregulator acts predominantly in the organ or system from which its parent regulatory peptide originated — pineal-derived peptides act in the pineal axis, thymus-derived peptides act on T-cell competence, vascular-derived peptides act on endothelial function, and so on. This tissue-specificity is one of the discipline's defining characteristics and a source of its therapeutic breadth across neurological, immune, vascular, longevity, and metabolic indications.